Does intra-renal delivery of mesenchymal stem cells attenuate myocardial injury after reversal of hypertension in porcine renovascular disease?
Intra-renal MSC delivery during PTRA preserved stenotic-kidney function, reduced systemic oxidative stress and inflammation, and thereby improved cardiac function, oxygenation, and myocardial injury four weeks after revascularization, suggesting a therapeutic potential for adjunctive MSC delivery to preserve cardiac function and structure after reversal of experimental RVH.
The incidence of BV in this study was lower than that described in other populations. No clinical complications occurred among the BV-positive women. Screening for BV prior to IUD insertion is neither currently recommended, nor supported by our study findings.